COGNEX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for COGNEX (COGNEX).
Reversible acetylcholinesterase inhibitor, increases acetylcholine concentration at cholinergic synapses.
| Metabolism | Primarily hepatic via CYP1A2 and other cytochrome P450 enzymes; extensive first-pass metabolism. |
| Excretion | Primarily renal (approximately 40-60% as unchanged drug and metabolites) and biliary/fecal (approximately 20-30%). |
| Half-life | Terminal elimination half-life is approximately 7-10 hours; clinical context: allows twice-daily dosing in most patients. |
| Protein binding | Approximately 40% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 1.7 L/kg; indicates moderate tissue distribution, including penetration into the central nervous system. |
| Bioavailability | Oral bioavailability is approximately 30-40% due to extensive first-pass metabolism. |
| Onset of Action | Oral: clinical effects observed within 2-4 weeks; peak effect may take several months. |
| Duration of Action | Duration of action is 8-12 hours following each dose; clinical notes: sustained cholinesterase inhibition requires regular dosing. |
| Action Class | Nootropic agent |
| Brand Substitutes | Vanocit Tablet |
Initial dose 10 mg orally 4 times daily (40 mg/day); may increase by 10 mg/day every 6 weeks up to 160 mg/day (40 mg 4 times daily).
| Dosage form | CAPSULE |
| Renal impairment | For CrCl < 30 mL/min, reduce dose to 10 mg orally twice daily (20 mg/day) and titrate slowly. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce maintenance dose by 50%. Child-Pugh Class C: Use not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | Consider age-related renal impairment; use lower initial doses (e.g., 10-20 mg/day) and titrate cautiously. Monitor for increased adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for COGNEX (COGNEX).
| Breastfeeding | Excretion in human milk is unknown. Because many drugs are excreted in human milk and due to potential for serious adverse reactions in nursing infants (e.g., cholinergic effects, hepatotoxicity), a decision should be made to discontinue nursing or discontinue the drug. M/P ratio: not available. |
| Teratogenic Risk | Pregnancy Category C. In animal studies, tacrine (Cognex) was associated with decreased fetal weight and increased incidence of skeletal variations at doses 3-6 times the maximum human dose. No adequate human studies exist. First trimester: potential risk cannot be ruled out. Second and third trimesters: unknown fetal effects. Use only if benefit outweighs potential risk. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to tacrine or acridine derivatives.","Patients with prior jaundice attributed to tacrine."]
| Precautions | ["Cholinergic effects may cause bradycardia and syncope.","Monitor for gastrointestinal bleeding, especially in patients at risk.","May exacerbate asthma or urinary obstruction.","Use with caution in patients with a history of peptic ulcer disease."] |
Loading safety data…
| Fetal Monitoring | Monitor liver function tests (ALT, AST) weekly for first 18 weeks, then monthly for 2 months, then every 3 months. Monitor for cholinergic adverse effects (bradycardia, hypotension, seizures, urinary obstruction). Fetal monitoring (ultrasound, non-stress test) as clinically indicated due to maternal cholinergic stimulation. |
| Fertility Effects | No data in humans. In animal studies, no effects on fertility were observed in rats at doses up to 10 mg/kg/day. Theoretical potential for cholinergic effects on reproductive tract motility. |